

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sanai Health Industry Group Company Limited

三愛健康產業集團有限公司

(formerly known as Wuyi International Pharmaceutical Company Limited

武夷國際藥業有限公司)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

**(1) DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT
FOR THE YEAR ENDED 31 DECEMBER 2017
(2) POSTPONEMENT OF BOARD MEETING
AND
(3) SUSPENSION OF TRADING**

This announcement is made by Sanai Health Industry Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2) and 13.49(3) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Delay in Publication of Annual Results Announcement for the year ended 31 December 2017

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that the Company will not be able to publish the announcement (the “**Results Announcement**”) in respect of the consolidated results of the Group for the year ended 31 December 2017 (the “**2017 Audited Results**”) on or before 31 March 2018 as the Company requires more time and resources to prepare the 2017 Audited Results and resolve the requests from the independent auditor of the Company, Crowe Horwath (HK) CPA Limited (the “**Auditor**”), and the Auditor requires more time to complete the audit of 2017 Audited Results.

The expected date of the publication of the Results Announcement will need to be further agreed with the Auditor and will be announced as and when appropriate.

Pursuant to Rule 13.49(1) of the Listing of Rules, the Company is required to publish the Results Announcement on or before 31 March 2018. The Board acknowledges that the delay in the publication of the Results Announcement will constitute a non-compliance of Rule 13.49(1) of the Listing Rules.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to publish its preliminary results in accordance with the requirements of the Listing Rules, it must announce its results based on the financial results which have yet to be agreed with the independent auditor (so far as the information is available). After due and careful consideration, the Board formed the view that as the financial data in relation to the unaudited management accounts of the Group are still being reviewed and finalized by the Company and that the Auditor requires more time to form an opinion on such financial data, it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended 31 December 2017 for the time being as it may be misleading and confusing to shareholders and potential investors.

Postponement of Board Meeting

Reference is made to the announcement of the Company dated 16 March 2018 in relation to the Board meeting to be held on 29 March 2018. As a result of the delay in the finalization of the 2017 Audited Results, the Board meeting for the purposes of, among other matters, considering and approving the 2017 Audited Results is therefore postponed to another date to be fixed by the Board.

Suspension of Trading

At the request of the Company, trading in the Company's shares on the Stock Exchange will be suspended with effect from 9:00 a.m. on 3 April 2018 pending the publication of the Results Announcement.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sanai Health Industry Group Company Limited
Chen Chengqing
Chairman

Hong Kong, 29 March 2018

As at the date of this announcement, the Board comprises 3 executive directors, namely, Mr. Chen Chengqing (Chairman), Ms. Hung Hoi Lan and Professor Zhang Rongqing, and 3 independent non-executive directors, namely, Mr. Wang Zihao, Mr. Tu Fangkui and Mr. Long Jun.